| Marianna Ruhl, CRNP | |
|
700 Lancaster Rd, Manheim, PA 17545-2314 | |
| (717) 665-2496 | |
| (717) 665-6345 |
| Full Name | Marianna Ruhl |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 700 Lancaster Rd, Manheim, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346721982 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | SP018984 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Medical Group | 0941103683 | 463 |
News Archive
Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.
Researchers at Mount Sinai School of Medicine say the immune system might contribute to the tumor heterogeneity seen in liver cancer that can affect the rate of cancer growth.
› Verified 2 days ago
| Entity Name | Lancaster General Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952392383 PECOS PAC ID: 0941103683 Enrollment ID: O20040309000916 |
News Archive
Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.
Researchers at Mount Sinai School of Medicine say the immune system might contribute to the tumor heterogeneity seen in liver cancer that can affect the rate of cancer growth.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marianna Ruhl, CRNP 700 Lancaster Rd, Manheim, PA 17545-2314 Ph: (717) 665-2496 | Marianna Ruhl, CRNP 700 Lancaster Rd, Manheim, PA 17545-2314 Ph: (717) 665-2496 |
News Archive
Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.
ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.
Researchers at Mount Sinai School of Medicine say the immune system might contribute to the tumor heterogeneity seen in liver cancer that can affect the rate of cancer growth.
› Verified 2 days ago
Dr. Nicholas A Buckwalter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 107 W End Dr, Manheim, PA 17545 Phone: 717-721-4860 Fax: 717-664-5028 | |
Debanjana Chakrabarti, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 S Penn St, Manheim, PA 17545 Phone: 717-665-2496 Fax: 717-665-6345 | |
William D.l. Hunt, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 130 S Penn St, Manheim, PA 17545 Phone: 717-665-2496 Fax: 717-665-6345 | |
Terrence H Jones, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 130 S Penn St, Manheim, PA 17545 Phone: 717-665-2496 Fax: 717-665-6345 | |
Dr. Janna G Semenuk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 S Penn St, Manheim, PA 17545 Phone: 717-665-2496 | |
Eugene K Engle, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 80 Doe Run Rd, Manheim, PA 17545 Phone: 717-664-0952 Fax: 717-664-0955 |